Bard Associates Inc Biofrontera Inc. Transaction History

Bard Associates Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.4 - $0.65 $2,800 - $4,550	-7,000 Reduced 3.53%	191,200 $99,000
Q4 2022 Feb 10, 2023	SELL	$0.77 - $24.8 $42,407 - $1.37 Million	-55,075 Reduced 21.75%	198,200 $182,000
Q3 2022 Nov 09, 2022	SELL	$0.82 - $41.8 $4,920 - $250,799	-6,000 Reduced 2.31%	253,275 $266,000
Q2 2022 Aug 11, 2022	BUY	$37.2 - $99.2 $491,040 - $1.31 Million	13,200 Added 5.36%	259,275 $482,000
Q1 2022 May 11, 2022	SELL	$45.0 - $138.4 $4.36 Million - $13.4 Million	-96,950 Reduced 28.26%	246,075 $819,000
Q4 2021 Feb 14, 2022	BUY	$49.4 - $263.4 $16.9 Million - $90.4 Million	343,025 New	343,025 $2.58 Million

Ticker BFRI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 23,551,000
Market Cap $22.6M
Description
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for phot...

Get notified when there are updates to the investment portfolio of Bard Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Bard Associates Inc with notifications on news.